Paper · 31912902

Cancer statistics, 2020.

Siegel RL and 2 others. CA Cancer J Clin, 2020. Cited by 16,920 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. Cancer statistics, 2020. Papers, record 31912902. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/31912902

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: Cancer statistics, 2020.; PubMed
Journal: CA Cancer J Clin; PubMed
Year: 2020; PubMed
Publication types: Journal Article, Multicenter Study; PubMed
PubMed: https://pubmed.ncbi.nlm.nih.gov/31912902/; PubMed
DOI: https://doi.org/10.3322/caac.21590; PubMed
The journal: https://conductscience.org/library/journal-index/0370647; PubMed
Citations, by iCite: 16,920; iCite
Relative citation ratio, by iCite: 1,040; iCite
Revised in PubMed: 2020-09-08; PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename	ORCID iD
1	Siegel RL	Rebecca L	https://orcid.org/0000-0001-5247-8522
2	Miller KD	Kimberly D	https://orcid.org/0000-0002-2609-2260
3	Jemal A	Ahmedin

Source PubMed

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
American Cancer Society	Major topic
Neoplasms	Major topic
Registries	Major topic
SEER Program	Major topic
Adult
Aged
Female
Humans
Incidence
Male
Middle Aged
Survival Rate
United States
Young Adult

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials42

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

Trial	Title	The trial lists it as	Source
NCT04338438	Efficacy and Safety of Apatinib Combined With S-1 for Patients With Advance Gastric Cancer	Background	ClinicalTrials.gov
NCT04403984	Investigation of Genomic Alteration in Patients With Luminal A or Luminal B Subtypes	Background	ClinicalTrials.gov
NCT04677192	Microwave Ablation Combined With Chemotherapy in the Treatment of Pancreatic Cancer Oligohepatic Metastasis	Background	ClinicalTrials.gov
NCT04702009	Efficacy and Safety of First-line Anti-PD-1/PD-L1 Monoclonal Antibody in Combination With Chemotherapy and Bronchoscopy-assisted Interventional Therapy in Patients With Advanced Central Non-small Cell Lung Cancer	Background	ClinicalTrials.gov
NCT04736108	Neoadjuvant Therapy of Abiraterone Plus ADT for Intraductal Carcinoma of the Prostate	Background	ClinicalTrials.gov
NCT04750772	Positron Nuclide Labeled DOTA-FAPI PET Study in Colocrectal Cancer	Results	ClinicalTrials.gov
NCT04787991	Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma	Background	ClinicalTrials.gov
NCT04923529	TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma	Background	ClinicalTrials.gov
NCT05006131	Pancreatic Cancer Screening for At-risk Individuals	Background	ClinicalTrials.gov
NCT05033691	A Study to Evaluate the Efficacy of Osimertinib With Early Intervention SRS Treatment Compared to the Continuation of Osimertinib Alone, in Patients With EGFR Mutated NSCLC and Asymptomatic Brain Metastases	Background	ClinicalTrials.gov

1 to 10 of 42

See all 42 trials

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

Kind	PMID	Title	In Papers
Comment in	31,965,108	Our best weapons against cancer are not magic bullets.	https://conductscience.org/library/papers/31965108

Source PubMed

References0

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

None in this release.

Cited by12,264

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 16,920 citations.

PMID	Title	Journal	Year	In Papers	Source
42,979,670	Incorporating natural language processing-derived features from pathology reports into machine learning models to predict differentiated thyroid cancer recurrence.	Front Endocrinol (Lausanne)	2026	https://conductscience.org/library/papers/42979670	PubMed
42,972,341	Assessing the reliability of AI-generated responses to patient-oriented lung cancer questions: a multi-platform study.	BMC Pulm Med	2026	https://conductscience.org/library/papers/42972341	PubMed
42,968,953	Larger Non-metastatic No. 8 Lymph Node Size Is Associated With Favorable Prognosis After Pancreaticoduodenectomy for Pancreatic Cancer.	Cancer Diagn Progn	2026	https://conductscience.org/library/papers/42968953	PubMed
42,967,976	Psychometric properties of the Functional Assessment of Cancer Therapy-Lung (FACT-L) scale to measure health-related quality of life.	J Patient Rep Outcomes	2026	https://conductscience.org/library/papers/42967976	PubMed
42,959,893	Expression analysis of potential novel biomarkers TRIM29 alongside lncRNA NORAD and MIR497-HG in breast, gastric, and colorectal cancers.	Mol Genet Metab Rep	2026	https://conductscience.org/library/papers/42959893	PubMed
42,958,457	Evaluating the psychosocial benefits of mindfulness-based art therapy for breast cancer patients: a preliminary study.	BMC Psychol	2026	https://conductscience.org/library/papers/42958457	PubMed
42,958,071	Prognostic value of Gli1 expression on colorectal cancer: a retrospective study.	BMC Gastroenterol	2026	https://conductscience.org/library/papers/42958071	PubMed
42,948,049	DNA polymerase ε-mutant endometrial carcinosarcoma: A case report and literature review.	Exp Ther Med	2026	https://conductscience.org/library/papers/42948049	PubMed
42,942,068	CAV1 as a Potential Regulator of Endothelial-Macrophage Communication Through the CD74/MIF Pathway in Breast Cancer.	Int J Mol Sci	2026	https://conductscience.org/library/papers/42942068	PubMed
42,938,162	Radiomics-Based Outcome Prediction in Transarterial Radioembolization (TARE) of Hepatic Malignancies: A Systematic Review and Quality Appraisal.	Diagnostics (Basel)	2026	https://conductscience.org/library/papers/42938162	PubMed

1 to 10 of 12,264

See all 12,264 cited by

Genes0

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

None in this release.

Drugs3

The drugs whose trials, in the Pipelines release, list the paper.

Drug	ChEMBL ID	The trials list it as	Trials	In Drugs and targets	Source
CAPECITABINE	CHEMBL1773	Results	1	https://conductscience.org/library/drugs/CHEMBL1773	ChEMBL
FLUOROURACIL	CHEMBL185	Results	1	https://conductscience.org/library/drugs/CHEMBL185	ChEMBL
OXALIPLATIN	CHEMBL414804	Results	1	https://conductscience.org/library/drugs/CHEMBL414804	ChEMBL

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/31912902

GET https://conductscience.org/api/papers/v1/31912902/trials?page=2

API reference For AI assistants